Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BGM vs BHST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BGM Captures Overall Composite Edge (59.6 HOLD vs 58.2 HOLD), While BHST Leads 3–2 on Growth & Valuation Pillars

BGM Overall Winner 6-Pillar Tally: BGM 2 – 3 BHST (1 Tie) Matrix Metrics: BGM 6 – 2 BHST

As of Nov 20, 2026, BGM Group Ltd. Class A (BGM) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (59.6/100 HOLD vs. 58.2/100 HOLD) after splitting the core matrix 6–2 (led by Growth & Scale, Balance Sheet & Cash Flow), while BHST wins 3–2 across the 6-pillar growth and valuation breakdown. BGM trades at $8.00 (N/M Forward P/E, -23.4% operating margin) versus BHST at $1.30 (N/M Forward P/E, -18.0% operating margin).

  • Growth vs. Quality Trade-Off: BGM earns the overall head-to-head edge with a stronger Unified Composite Score (59.6/100 HOLD vs. BHST 58.2/100 HOLD) and 3.69β · 80% Vol risk profile, whereas BHST leads top-line expansion (+3.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BGM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 53.8); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BGM vs BHST
BGM NASDAQ Head-to-Head Winner
BGM Group Ltd. Class A Ordinary Shares
Pharmaceutical Preparations
$8.00
-1.6% 1D
Market Cap $108.6M
TTM Revenue $48M
Forward P/E N/M
Beta / 30D Vol 3.69β · 80% Vol
Unified Composite Score
59.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (167.7% over 20 days), RSI 54
RSI-14: 53.8 · SMA20: $8.51 · SMA50: $5.25
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
TTM Revenue $35M
Forward P/E N/M
Beta / 30D Vol 0.25β · 86% Vol
Unified Composite Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 37
RSI-14: 37.2 · SMA20: $1.55 · SMA50: $1.58

6-Pillar Scorecard Institutional Category Breakdown (BGM 2 – 3 BHST)

Columns: Metric · BGM · BHST
1. Valuation Multiples BHST
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 2.3x 0.7x
2. Growth & Scale BGM
Revenue Growth (YoY) +69.8% +3.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $48M $35M
Market Cap $108.6M $29.9M
3. Profitability & Quality BHST
Gross Margin 16.9% 59.0%
Operating Margin -23.4% -18.0%
Net Profit Margin -44.2% -31.2%
Return on Equity (ROE) -7.4% -142.5%
4. Balance Sheet & Cash Flow BGM
Cash Generation (TTM) -$9.2M EBITDA -$9.4M
Cash Flow Margin -19.3% EBITDA Mgn -26.6%
Net Cash / Leverage $59.55 Book/Sh · -7.4% ROE $5.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BHST
OpEx & R&D Intensity 40.3% of Rev ($19M) 77.0% of Rev ($27M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Packaged Foods Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BGM (6) vs BHST (2)
Institutional Metric BGM BHST Criterion Row Edge
Market Capitalization
Scale
$108.6M $29.9M Larger Scale BGM
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+69.8% +3.8% Higher Growth BGM
Operating Margin (TTM)
Profitability
-23.4% -18.0% Higher Margin BHST
Net Profit Margin
Profitability
-44.2% -31.2% Higher Margin BHST
Return on Equity (ROE)
Capital Efficiency
-7.4% -142.5% Higher ROE BGM
52-Week Range Position
Momentum
74% ($0–$11) 6% ($1–$7) Stronger Trend BGM
Beta / 30D Volatility
Risk Regime
3.69β · 80% Vol 0.25β · 86% Vol Lower Realized Risk BGM
Unified Institutional Score
Composite Signal
59.6 / 100 (HOLD) 58.2 / 100 (HOLD) Higher Composite BGM
Trailing 12M Revenue (USD)
Operating Scale
$48M $35M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.9% 59.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.3x EV/Rev N/M PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.2M EBITDA ($59.55 Book/Sh · -7.4% ROE) -$9.4M ($5.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BHST +3.05 pp
BGM: -21.57% · BHST: -18.52%
3M Horizon BGM +2712.53 pp
BGM: +2673.93% · BHST: -38.6%
6M Horizon BGM +3028.41 pp
BGM: +2962.79% · BHST: -65.62%
1Y Horizon BGM +73.31 pp
BGM: -5.77% · BHST: -79.08%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGM vs BHST. Trailing 12-month operating profitability (BGM -23.4% vs BHST -18.0%) and valuation multiples (BGM N/M vs BHST N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BGM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$48M
Gross Margin16.9%
Op. Margin-23.4%
ROE / Fwd P/E-7.4% · N/M
BHST ADR TTM Benchmark FX-Normalized USD
TTM Revenue$35M
Gross Margin59.0%
Op. Margin-18.0%
ROE / Fwd P/E-142.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BGM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BGM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BHST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BHST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BGM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $108.6M market capitalization and -23.4% operating margin.
OpEx & R&D Reinvestment 40.3% of Rev ($19M)
90D Engineering Disclosures 0 Published
BHST Moat Profile Cyclical / Execution-Driven Positioning
Packaged Foods Operator
Competes within the Packaged Foods value chain with $29.9M market capitalization and -18.0% operating margin.
OpEx & R&D Reinvestment 77.0% of Rev ($27M)
90D Engineering Disclosures 0 Published

Investor FAQ BGM vs BHST Key Questions & Quantitative Answers

As of Nov 20, 2026, BGM Group Ltd. Class A (BGM) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (59.6/100 HOLD vs. 58.2/100 HOLD) after splitting the core matrix 6–2 (led by Growth & Scale, Balance Sheet & Cash Flow), while BHST wins 3–2 across the 6-pillar growth and valuation breakdown. BGM trades at $8.00 (N/M Forward P/E, -23.4% operating margin) versus BHST at $1.30 (N/M Forward P/E, -18.0% operating margin). Growth vs. Quality Trade-Off: BGM earns the overall head-to-head edge with a stronger Unified Composite Score (59.6/100 HOLD vs. BHST 58.2/100 HOLD) and 3.69β · 80% Vol risk profile, whereas BHST leads top-line expansion (+3.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BGM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 53.8); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BGM leads the Growth & Scale pillar: BGM posts +69.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (16.9% gross margin, -23.4% operating margin), compared with BHST at +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin). On trailing 12-month operating scale, BGM generates $48M in USD-normalized revenue versus $35M for BHST. In operating R&D and SG&A reinvestment, BGM deploys 40.3% of Rev ($19M) (0 90-day corporate R&D disclosures) versus 77.0% of Rev ($27M) (0 disclosures) for BHST.

BHST screens cheaper on headline valuation multiples. BGM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-19.3% EBITDA margin), whereas BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BGM (-7.4% ROE) versus BHST (-142.5% ROE) capital efficiency.

In options market volatility and institutional positioning, BGM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.69β · 80% Vol realized risk). By comparison, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.